Financials
Financial year 2025
CURAPHARMA from Zaventem, company number BE0878122786, closed financial year 2025 with a result of € 7,040 after tax. For that financial year CURAPHARMA recorded a gross margin of € 17,427 and equity of € 134,902. Compared with financial year 2024, the result moved from € 9,787 to € 7,040. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 28, 2026.
€ 134,902
▲ 6% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 7,040
▼ 28% vs 2024
Profit after tax over the fiscal year.
€ 60,745
▼ 38% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 122,502.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 112,909
▼ 4% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 27,044 | € 44,858 | € 23,315 | € 17,427 | ▼ 25% |
| Profit after taxes | € 14,411 | € 31,581 | € 9,787 | € 7,040 | ▼ 28% |
| Equity | € 101,493 | € 118,074 | € 127,861 | € 134,902 | ▲ 6% |
| Total debts | € 249,543 | € 264,773 | € 258,828 | € 217,369 | ▼ 16% |
| Cash | € 66,490 | € 108,625 | € 98,567 | € 60,745 | ▼ 38% |
| Land & buildings | € 5,964 | € 5,726 | € 5,488 | € 5,251 | ▼ 4% |
| Retained profit | € 89,093 | € 105,674 | € 115,461 | € 122,502 | ▲ 6% |
| Dividend | € 0 | € 15,000 | € 0 | € 0 | |
| Balance sheet total | € 351,036 | € 382,847 | € 386,690 | € 352,271 | ▼ 9% |
Key figures of CURAPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CURAPHARMA?
What happened at CURAPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 7,040 (▼ 28% vs 2024). Source: NBB ↗
- New establishment in Zaventem. KBO
- Start of the company according to the CBE. KBO
- Krito Pharma BV became a director. NBB
In short
From € 14,411 profit in 2022 to € 7,040 profit in 2025.
Paid € 15,594 in corporate taxes since 2022.
Best year ever: 2023, with € 31,581 profit.
Paid out € 15,000 in dividends to the owners in total.
A new publication or filing at CURAPHARMA? We notify you, reason included.
Follow CURAPHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of KRITO PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
CURAPHARMABehind CURAPHARMA is Krito Pharma BV. The shares are held by KRITO PHARMA (100%).
Directors
According to the 2025 annual accounts
Director · represented by Tom Lamote
since 2005
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Watertorenlaan 1
1930 Zaventem
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0878.122.786
- VAT number
- BE 0878.122.786
- Registered office
- Watertorenlaan 1, 1930 Zaventem
- Names & denominations
- CURAPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 December 2005
- Peppol
- Active · Active since 8 May 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers
Detailhandel in cosmetica en toiletartikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels